<DOC>
	<DOCNO>NCT02998528</DOCNO>
	<brief_summary>The purpose study determine safety effectiveness nivolumab ipilimumab compare chemotherapy treatment Early Stage Non-Small Cell Lung Cancer .</brief_summary>
	<brief_title>A Neoadjuvant Study Nivolumab Ipilimumab Compared Chemotherapy Doublet Early Stage Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BristolMyers Squibb Clinical Trial participation , please visit www.BMSStudyConnect.com Early stage IBIIIA , operable nonsmall cell lung cancer , confirm tissue Lung function capacity capable tolerating propose lung surgery Eastern Cooperative Oncology Group ( ECOG ) Performance Status 01 Available tissue primary lung tumor Presence locally advance , inoperable metastatic disease Participants active , know suspected autoimmune disease Prior treatment drug target T cell costimulations pathway ( checkpoint inhibitor ) Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>